Overview
- The site is Novartis’ first Texas manufacturing facility and its fifth U.S. radioligand therapy location.
- Construction is slated to start this year with commercial operations targeted for 2028.
- Novartis expects to hire across bioengineering, advanced manufacturing, quality and operations.
- The plant will integrate with an RLT network spanning New Jersey, Indiana and California, with a new site planned in Florida, which the company says enables more than 99% of doses to be delivered on schedule.
- Denton approved a $3.2 million incentive package in December tied to at least 150 jobs and an investment that local reports place at about $280 million, including more than $70 million in facility upgrades and around $200 million in equipment.